Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan 11;383(9912):166-75.
doi: 10.1016/S0140-6736(13)62227-8. Epub 2014 Jan 8.

Increasing value and reducing waste in research design, conduct, and analysis

Affiliations

Increasing value and reducing waste in research design, conduct, and analysis

John P A Ioannidis et al. Lancet. .

Abstract

Correctable weaknesses in the design, conduct, and analysis of biomedical and public health research studies can produce misleading results and waste valuable resources. Small effects can be difficult to distinguish from bias introduced by study design and analyses. An absence of detailed written protocols and poor documentation of research is common. Information obtained might not be useful or important, and statistical precision or power is often too low or used in a misleading way. Insufficient consideration might be given to both previous and continuing studies. Arbitrary choice of analyses and an overemphasis on random extremes might affect the reported findings. Several problems relate to the research workforce, including failure to involve experienced statisticians and methodologists, failure to train clinical researchers and laboratory scientists in research methods and design, and the involvement of stakeholders with conflicts of interest. Inadequate emphasis is placed on recording of research decisions and on reproducibility of research. Finally, reward systems incentivise quantity more than quality, and novelty more than reliability. We propose potential solutions for these problems, including improvements in protocols and documentation, consideration of evidence from studies in progress, standardisation of research efforts, optimisation and training of an experienced and non-conflicted scientific workforce, and reconsideration of scientific reward systems.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

We declare that we have no conflicts of interest.

Figures

Figure
Figure. Trends in three methodological quality indicators for reports of in-vivo studies
We randomly sampled 2000 records from PubMed (published 1960–2012) on the basis of their PubMed ID (see appendix for details and the study dataset). 254 reports described in-vivo, ex-vivo, or in-vitro experiments involving non-human animals. Two investigators independently judged whether blinded assessment of outcome, randomisation, or a conflicts of interest statement were included. The proportion reports including this information is described in quintiles of publication year, along with their 95% CI. Sample size calculation, concealment of allocation sequence, or blinded conduct of the experiment were not reported for any study, so are not shown. The appendix contains detailed protocol, data extraction process, flow diagram, and raw data.

References

    1. Khoury MJ, Clauser SB, Freedman AN, et al. Population sciences, translational research, and the opportunities and challenges for genomics to reduce the burden of cancer in the 21st century. Cancer Epidemiol Biomarkers Prev. 2011;20:2105–14. - PMC - PubMed
    1. García-Berthou E, Alcaraz C. Incongruence between test statistics and P values in medical papers. BMC Med Res Methodol. 2004;4:13. - PMC - PubMed
    1. Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov. 2011;10:712–13. - PubMed
    1. Begley CG, Ellis LM. Drug development: raise standards for preclinical cancer research. Nature. 2012;483:531–33. - PubMed
    1. Pereira TV, Ioannidis JP. Statistically significant meta-analyses of clinical trials have modest credibility and inflated effects. J Clin Epidemiol. 2011;64:1060–69. - PubMed